

Global CD40 Targeted Therapies Clinical Trials, Therapeutic Approaches, Proprietary Technology Platforms & Market Opportunity Insight 2026

<https://marketpublishers.com/r/GC25A8AA8978EN.html>

Date: October 2025

Pages: 120

Price: US\$ 2,800.00 (Single User License)

ID: GC25A8AA8978EN

Abstracts

Findings & Highlights:

First CD40 Targeted Therapy Approval Expected By 2027

CD40 Targeted Therapies In Clinical Trials: > 35 Therapies

CD40 Targeted Therapies Clinical Trials Insight By Company, Country, Indication and Phase

CD40 Targeted Therapies Proprietary Technologies By Company

CD40 Targeted Therapy Market Trend Analysis By Region

Competitive Landscape

Need For CD40 Targeted Therapies & Why This Report?

CD40 targeting therapies are now emerging as a major breakthrough in immunotherapy, holding new promise for autoimmune disease, cancer, and even for certain infectious diseases. In contrast to conventional treatments, which generally dampen the immune system in a broad way, CD40 targeting therapies seek to modulate immune reactions specifically by selectively targeting the CD40 receptor on immune cells. This method may result in better and safer therapies because it can modulate the immune system without leading to the generalized immune suppression and side effects

of traditional treatments. With continued encouraging findings from clinical trials, CD40 targeted therapy is being investigated for autoimmune diseases such as lupus nephritis, multiple sclerosis, and cancer, marking a groundbreaking change in the treatment of these intricate illnesses.

The report presents a detailed analysis of the emerging CD40 targeted therapy market, aimed at keeping stakeholders up to date with the recent advancements and upcoming trends. The report provides unique insights into current clinical trials, major pharmaceutical companies, and the most promising pipeline drug candidates. Additionally, the report explores technological innovations and collaborative initiatives that are driving the development of more targeted and efficacious CD40 targeting therapies. With both a snapshot of the present state of the market as well as its future potential, the report arms investors, researchers, and healthcare professionals alike with critical information to make sense of this fast developing space.

Clinical Trials Insight Covered In Report

With clinical trials remaining central to the development of CD40 targeted therapies, this report looks closely at the ongoing and upcoming trials that are defining the future of the therapies. Phase trials have already demonstrated encouraging results, with certain therapies progressing to Phase 3 trials for autoimmune conditions. Such trials serve not only to develop the therapeutic potential of CD40 targeting agents but also to determine which drug candidates have the greatest likelihood of success in the larger market.

The report also briefly addresses the increasing demand for such therapies in global markets. As great a lead as the US has taken with CD40 targeted research, there has been a growing presence of trials in other areas, including China, Australia, and parts of Europe. The fact that this geographical presence is broadening reflects the fact that CD40 targeted therapies are now being considered all over the world, with new opportunities in different healthcare markets.

Top Companies Involved In R&D Of CD40 Targeting Therapy

A number of top pharmaceutical companies, in addition to cutting edge biotech companies, are leading research and development in CD40 targeted therapy. These corporations are breaking the mold, innovating new therapies that have the potential to profoundly transform the treatment of autoimmune diseases, cancers, and more. Some candidates are in later clinical stages, while others are still in early development but are indicating encouraging preclinical data.

This report highlights the efforts of leading players in the industry that are pioneering the research in CD40 targeting therapies. These players are making use of advanced technologies and scientific innovations to enhance the safety and efficacy of the therapies. Alliances and collaboration between pharmaceutical firms, biotech companies, and academia are also speeding up the process of development, establishing a collaborative system that will culminate in breakthroughs in the near term.

Technology Platforms, Partnerships & Agreements

Much of the report is dedicated to the technological advancements that are making it possible to design more potent and targeted CD40 treatments. Novel platforms are being applied by companies to increase the specificity of CD40 targeting, reducing side effects while maximizing therapeutic effect. The case in point is incorporating monoclonal antibodies and antigens to target dendritic cells, which might increase the immune response in a more precise and long lasting fashion.

Pharma, biotech, and academic collaborations are also speeding up the innovation rate in the field. The collaborations are needed to overcome the complexity issues related to the development of CD40 targeted therapy, including optimization of the delivery mechanisms as well as long term safety issues. The report highlights some of the collaborations and alludes to the promising advances being made in the field.

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Contents

1. INTRODUCTION TO CD40 TARGETED THERAPIES

- 1.1 Overview
- 1.2 Considering CD40 As Drug Target Over Other CD Markers
- 1.3 History & Evolution Of CD40 Targeting Therapies

2. CD40 TARGETED THERAPIES ? MECHANISM OF ACTION

- 2.1 Agonist Mediated Activation Of CD40 Signaling
- 2.2 Antagonist Mediated Inhibition Of CD40 Signaling

3. CD40 TARGETED THERAPEUTIC APPROACHES

- 3.1 Antibody Formats
- 3.2 Fusion Proteins
- 3.3 Peptides
- 3.4 Nucleic Acids

4. CD40 TARGETED THERAPY RESEARCH & DEVELOPMENT TRENDS BY INDICATION

- 4.1 Cancer
- 4.2 Neurological Diseases
- 4.3 Autoimmune & Inflammatory Disorders
- 4.4 Transplant Rejection
- 4.5 Microbial Infections

5. CD40 TARGETED THERAPIES CLINICAL TRIALS INSIGHT BY COMPANY, COUNTRY, INDICATION & PHASE

- 5.1 Research
- 5.2 Preclinical
- 5.3 Phase I
- 5.4 Phase I/II
- 5.5 Phase II
- 5.6 Phase III

6. GLOBAL CD40 TARGETED THERAPY MARKET OUTLOOK

- 6.1 Current Market Trends & Developments
- 6.2 Future Market Opportunities

7. CD40 TARGETED THERAPY MARKET TREND ANALYSIS BY REGION

- 7.1 US
- 7.2 Europe
- 7.3 China
- 7.4 Japan
- 7.5 Australia

8. CD40 TARGETED THERAPIES - PROPRIETARY TECHNOLOGIES BY COMPANY

9. GLOBAL CD40 TARGETED THERAPY MARKET DYNAMICS

- 9.1 Drivers & Opportunities
- 9.2 Challenges & Restraints

10. COMPETITIVE LANDSCAPE

- 10.1 Alligator Bioscience
- 10.2 Amgen
- 10.3 Biogen
- 10.4 BioNTech
- 10.5 Eledon Pharmaceuticals
- 10.6 EnnoDC
- 10.7 Genmab
- 10.8 Innovent Bio
- 10.9 Novartis
- 10.10 Sanofi
- 10.11 Tonix Pharmaceuticals
- 10.12 UCB

List Of Tables

LIST OF TABLES

Table 3-1: Comparison Of siRNA vs. Anti-CD40 Antibody Therapy

Table 5-1: CD40 Targeted Therapies In Research Stage, 2025 - 2026

Table 5-2: CD40 Targeted Therapies In Preclinical Stage, 2025 - 2026

Table 5-3: CD40 Targeted Therapies In Phase I, 2025 - 2026

Table 5-4: CD40 Targeted Therapies In Phase I/II, 2025 - 2026

Table 5-5: CD40 Targeted Therapies In Phase II, 2025 - 2026

Table 5-6: CD40 Targeted Therapies In Phase III, 2025 - 2026

Table 6-1: CD40 Targeted Therapies In Phase III Clinical Trials

List Of Figures

LIST OF FIGURES

Figure 1-1: CD40 ? Salient Features

Figure 1-2: CD40 Targeted Therapy Landscape ? Major Milestones

Figure 2-1: CD40 Agonists ? Mechanism Of Action

Figure 2-2: CD40 Antagonists ? Mechanism Of Action

Figure 3-1: Prominent Antibody Formats For Targeting CD40

Figure 3-2: CD40 Fusion Protein Types & Properties

Figure 3-3: CD40 Fusion Proteins - Advantages & Challenges

Figure 3-4: Advantages vs. Challenges Of Peptides For CD40 Targeting

Figure 3-5: siRNA Delivery Mechanism & Effect On Immune Cells

Figure 4-1: OPTIMIZE-1 Phase 1b/2 (NCT04888312) Study ? Initiation & Completion Year

Figure 4-2: Mitazalimab Phase 1 (NCT06205849) Study ? Initiation & Completion Year

Figure 4-3: 2141-V11 Phase 1 (NCT06455605) Study ? Initiation & Completion Year

Figure 4-4: 2141-V11 Phase 1/2 (NCT05734560) Study ? Initiation & Completion Year

Figure 4-5: 2141-V11 Phase 1/2 (NCT05126472) Study ? Initiation & Completion Year

Figure 4-6: ACT16877 Phase 2 (NCT04879628) Study ? Initiation & Completion Year

Figure 4-7: FREVIVA Phase 3 (NCT06141486) Study ? Initiation & Completion Year

Figure 4-8: FREXALT 3 (NCT06141473) Study ? Initiation & Completion Year

Figure 4-9: PHOENYCS FLY Phase 3 (NCT06617325) Study ? Initiation & Completion Year

Figure 4-10: SL0046 Phase 3 (NCT04976322) Study ? Initiation & Completion Year

Figure 4-11: HZNP-DAZ-301 Phase 3 (NCT06104124) Study ? Initiation & Completion Year

Figure 4-12: HZNP-DAZ-303 Phase 3 (NCT06245408) Study ? Initiation & Completion Year

Figure 4-13: VIBRANT Phase 2 (NCT05201469) Study ? Initiation & Completion Year

Figure 4-14: FABULINUS Phase 2 (NCT06111586) Study ? Initiation & Completion Year

Figure 4-15: APB-A1 Phase 1b (NCT06557850) Study ? Initiation & Completion Year

Figure 4-16: IRB23-1367 Phase 1/2 (NCT06111586) Study ? Initiation & Completion Year

Figure 4-17: AT-1501-K102 Phase 1 (NCT05027906) Study ? Initiation & Completion Year

Year

Figure 4-18: BESTOW/AT-1501-K207 Phase 2 (NCT05983770) Study ? Initiation & Completion Year

Figure 4-19: BESTOW-EXTENSION/AT-1501-K209 Phase 2 (NCT06126380) Study ? Initiation & Completion Year

Figure 4-20: ANRS VRI06 Phase 1 (NCT04842682) Study ? Initiation & Completion Year

Figure 4-21: HVTN 318 Phase 1 (NCT06665646) Study ? Initiation & Completion Year

Figure 4-22: ANRS0407s - LKV.Cov40 Phase 1/2 (NCT06255626) Study ? Initiation & Completion Year

Figure 4-23: HPVDCVax Phase 1/2 (NCT06007092) Study ? Initiation & Completion Year

Figure 5-1: Global - CD40 Targeted Therapies In Clinical Trials, 2025 -2026

Figure 6-1: CD40 Targeted Therapy ? Future Opportunities

Figure 8-1: Alligator Bioscience - FIND technology

Figure 8-2: Alligator Bioscience - Neo-X-Prime

Figure 8-3: Aprilbio - SAFA Antibody APB-A1

Figure 8-4: Genmab ? DuoBody

Figure 8-5: Harbour BioMed - Harbour Mice

Figure 8-6: Harbour BioMed - HCAb

Figure 8-7: H2L2 & HCAb Platforms - Features

Figure 8-8: Harbour BioMed - HBICE

Figure 8-9: Kyowa Kirin - REGULGENT

Figure 8-10: ADAC Technology Platform - Features

Figure 8-11 Strike Pharma - ADAC Technology Platform

Figure 8-12: Strike Pharma - ADAC Molecule

Figure 9-1: CD40 Targeted Therapy Market - Drivers & Opportunities

Figure 9-2: CD40 Targeted Therapy Market - Challenges & Restraints

I would like to order

Product name: Global CD40 Targeted Therapies Clinical Trials, Therapeutic Approaches, Proprietary Technology Platforms & Market Opportunity Insight 2026

Product link: <https://marketpublishers.com/r/GC25A8AA8978EN.html>

Price: US\$ 2,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GC25A8AA8978EN.html>